Advances in Therapy

, Volume 35, Issue 6, pp 779–784 | Cite as

Application of Cu-64 NODAGA-PSMA PET in Prostate Cancer

  • Sabina Sevcenco
  • Hans Christoph Klingler
  • Klaus Eredics
  • Alexander Friedl
  • Jenifer Schneeweiss
  • Peter Knoll
  • Thomas Kunit
  • Lukas Lusuardi
  • Siroos Mirzaei
Original Research



The high diagnostic potential of 64Cu-PSMA PET–CT imaging was clinically investigated in prostate cancer patients with recurrent disease and in the primary staging of selected patients with advanced local disease. The aim of our study is to assess the uptake behavior in the clinical setting of 64Copper Prostate-Specific Membrane Antigen (64Cu PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) in prostate cancer.


A retrospective study was performed in 23 patients with intermediate, high risk and progressive disease at primary staging of prostate cancer. All patients underwent 64Cu-PSMA PET. Overall, 250 MBq (4 MBq per kg bodyweight, range 230–290 MBq) of 64Cu-NODAGA PSMA was intravenously applied. PET images were performed 30 min (pelvis and abdomen) and 1–2 h post-injection (skull base to mid-thigh). Maximum standardized uptake values (SUVmax) were measured in the organs with high physiological uptake such as liver and kidney, and, additionally, background activity was measured in the gluteal area and in suspected tumor lesions using a HERMES workstation.


PSMA uptake was detected in prostate bed in nine patients, in six patients in distant metastases (bone, lung and liver) and in nine patients in lymph nodes. Of 23 patients, 5 (20.8%) did not show any focal pathological uptake in the whole body. The number of sites (prostate bed, lymph nodes, distant metastases) with positive PSMA uptake was significantly associated with PSA values before imaging (P = 0.0032). The 64Cu PSMA uptake increased significantly from 30 min to 1–3 h post-injection (Wilcoxon signed rank test, P = 0.002).


64Cu NODAGA-PSMA PET is a promising imaging tool in the detection of residual disease in patients with recurrent or primary progressive prostate cancer. Furthermore, the increased tracer uptake over time indicates in vivo stability of the diagnostic radiopharmaceutical.


Copper PSMA Oncology Prostate cancer PSMA positron emission tomography/computed tomography (PSMA–PET–CT) Prostate-specific membrane antigen (PSMA) Standardized uptake values (SUV) 



We thank the participants of the study.


No funding or sponsorship was received for this study or publication of this article.


All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.


Sabina Sevcenco, Hans Christoph Klingler, Klaus Eredics, Alexander Friedl, Jenifer Schneeweiss, Peter Knoll, Thomas Kunit, Lukas Lusuardi and Siroos Mirzaei have nothing to disclose.

Compliance with Ethics Guidelines

All patients were examined with a standalone PET scanner (EXACT, Siemens, Erlangen, Germany) in compliance with the 1964 Declaration of Helsinki, and the responsible regulatory bodies in Austria. Formal consent was obtained from all patients prior to examination.

Data Availability

The manuscript has no associated data or the data will not be deposited.


  1. 1.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–37.CrossRefPubMedGoogle Scholar
  2. 2.
    von Eyben FE, Picchio M, von Eyben R et al., 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus. 2016;S2405–4569(16)30160–2.Google Scholar
  3. 3.
    Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56(8):1185–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Lutje S, Heskamp S, Cornelissen AS, et al. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics. 2015;5(12):1388–401.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rauscher I, Maurer T, Beer AJ, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med. 2016;57(11):1713–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Wadas TJ, Wong EH, Weisman GR, et al. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110(5):2858–902.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Farkas R, Siwowska K, Ametamey SM, et al. (64)Cu- and (68)Ga-based PET imaging of folate receptor-positive tumors: development and evaluation of an albumin-binding NODAGA-folate. Mol Pharm. 2016;13(6):1979–87.CrossRefPubMedGoogle Scholar
  8. 8.
    Grubmüller B, Baum RP, Capasso E, et al. 64Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: first in-human studies. Cancer Biother Radiopharm. 2016;31:277–86.CrossRefGoogle Scholar
  9. 9.
    Ghosh SC, Pinkston KL, Robinson H, et al. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates. Nucl Med Biol. 2015;42(2):177–83.CrossRefPubMedGoogle Scholar
  10. 10.
    Evangelista L, Briganti A, Fanti S, et al. New clinical indications for (18)F/(11)C-choline, new tracers for Positron Emission Tomography and a Promising Hybrid Device for prostate cancer staging: a systematic review of the literature. Eur Urol. 2016;70(1):161–75.CrossRefPubMedGoogle Scholar
  11. 11.
    Evangelista L, Luigi M, Cascini GL. New issues for copper-64: from precursor to innovative PET tracers in clinical oncology. Curr Radiopharm. 2013;6(3):117–23.CrossRefPubMedGoogle Scholar
  12. 12.
    Gourni E, Canovas C, Goncalves V, et al. (R)-NODAGA-PSMA: a versatile precursor for radiometal labeling and nuclear imaging of PSMA-positive tumors. PLoS ONE. 2015;10(12):e0145755.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Cantiello F, Gangemi V, Cascini GL, et al. Diagnostic accuracy of 64Copper prostate-specific membrane antigen positron emission tomography/computed tomography for primary lymph node staging of intermediate- to high-risk prostate cancer: our preliminary experience. Urology. 2017;106:139–45.CrossRefPubMedGoogle Scholar
  14. 14.
    Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Euro J Nucl Med Mol Imaging. 2015;42(2):197–209.CrossRefGoogle Scholar
  15. 15.
    Pillai MRA, Nanabala R, Joy A, et al. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: effective theranostic tools for imaging and therapy of prostate cancer. Nucl Med Biol. 2016;43(11):692–720.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2018

Authors and Affiliations

  • Sabina Sevcenco
    • 1
  • Hans Christoph Klingler
    • 2
  • Klaus Eredics
    • 1
  • Alexander Friedl
    • 3
  • Jenifer Schneeweiss
    • 3
  • Peter Knoll
    • 5
  • Thomas Kunit
    • 4
  • Lukas Lusuardi
    • 4
  • Siroos Mirzaei
    • 5
  1. 1.Department of UrologySMZ Ost, DonauspitalViennaAustria
  2. 2.Department of UrologyWilhelminenspitalViennaAustria
  3. 3.Department of UrologyKrankenhaus der Barmherzigen SchwesternViennaAustria
  4. 4.Department of UrologyParacelsus Medical UniversitySalzburgAustria
  5. 5.Department of Nuclear Medicine/PET-CenterWilhelminenspitalViennaAustria

Personalised recommendations